Cancer Genetics and Epigenetics

摘要 Sidney Kimmel综合癌症中心(SKCCC)癌症遗传学和表观遗传学(CGE) 该计划的总体目标是在细胞和细胞水平上加强对癌症发生和发展的了解 分子生物学水平。调查结果通过该计划内的试验进行翻译，更常见的情况是通过 与其他SKCCC项目合作，为临床试验和生物标记物工作贡献概念。这个 SKCCC优先定义了导致单个人类癌症的基因和表观遗传改变 以发展个性化的癌症护理。为实现其目标，CGE计划的领导层和成员 融入SKCCC的几乎所有活动，包括关键的行政活动、协作工作 几乎所有的SKCCC计划，以及SKCCC共享资源的利用和管理。这个 该计划由38个计划正式成员组成，其中31个成员拥有同行评审的资金，另外两个成员 准会员，包括在上一次资助期内获得活跃K奖的会员。该计划有 成员在约翰·霍普金斯大学两所学校的九个部门任职。总的直接癌症- 该项目的相关同行评审资金为1130万美元，其中770万美元来自国家癌症中心 研究所。自上次审查以来，按计划成员分列的出版物总数为807篇，其中197篇(24.4%) 其中383个(47.5%)是项目间合作，616个(76.3%)是外部合作。的 这些出版物中，23.4%是在影响因子为10的期刊上发表的，8.8%在影响因子为25的期刊上发表。 在Nilofer Azad医学博士、Stephen Baylin医学博士和Victor Velculescu博士的指导下， CGE方案的具体目标是： 目的1：定义驱动人类癌症发生和发展的基因异常， 尤其是那些可以接受治疗或诊断干预的患者。 目的2：研究肿瘤发生和发展的分子和表观遗传学改变。 进展，并利用这些信息来设计治疗策略和设计 生物标记物正在接近。 目标3：将基本发现转化为临床前研究，为临床提供概念 由CGE计划成员和其他SKCCC计划成员领导的研究人员发起的试验。 这些目标丰富了SKCCC的翻译目标，特别是在设计新的治疗范例方面 许多常见类型的人类恶性肿瘤，并在早期建立基于分子的生物标记物策略 癌症检测、预后预测和监测癌症进展。

ABSTRACT The Sidney Kimmel Comprehensive Cancer Center (SKCCC) Cancer Genetics and Epigenetics (CGE) Program's overall goal is to enhance understanding of the initiation and progression of cancer at a cellular and molecular biology level. Findings are translated through trials within the Program and, more often, by contributing concepts to clinical trials and biomarker efforts in collaboration with other SKCCC Programs. The SKCCC prioritizes the definition of the genetic and epigenetic alterations that drive individual human cancers in order to develop personalized cancer care. To implement its aims, CGE Program Leadership and Membership are integrated into virtually all activities in the SKCCC, including key administrative activities, collaborative work with virtually all of the SKCCC Programs, and utilization and management of SKCCC Shared Resources. The Program consists of 38 Program full Members, 31 of whom have peer-reviewed funding, and an additional two Associate Members, including one with an active K awards during this last funding period. The Program has members with appointments in nine departments across two schools at Johns Hopkins. The total direct cancer- relevant peer-reviewed funding for the Program is $11.3 million, with $7.7 million from the National Cancer Institute. The total number of publications by Program members since last review is 807, of which 197 (24.4%) are Intra-Programmatic, 383 (47.5%) are Inter-Programmatic and 616 (76.3%) have external collaborations. Of these publications, 23.4% are in journals with impact factors >10 and 8.8% in journals with impact factors >25. Under the direction of Nilofer Azad, M.D.; Stephen Baylin, M.D.; and Victor Velculescu, M.D., Ph.D., the Specific Aims of the CGE Program are: Aim 1: To define genetic abnormalities that drive human cancer initiation and progression, particularly those that may be amenable to therapeutic or diagnostic intervention. Aim 2: To characterize the molecular and epigenetic changes that underlie tumor initiation and progression, and harness this information to design therapeutic strategies and devise biomarker approaches. Aim 3: To translate basic findings to preclinical studies to provide concepts for clinical investigator-initiated trials led by CGE Program Members and other SKCCC Program Members. These aims enrich the translational goals of the SKCCC, particularly in designing new therapy paradigms for many common types of human malignancies and deriving molecularly based biomarker strategies for early cancer detection, prognostic prediction and monitoring cancer progression.